Yetu Coaching Group

Hemophilia Treatment: Bridging Tradition and Innovation

Introduction

Hemophilia, a rare genetic bleeding disorder caused by deficiencies in clotting factors VIII (Hemophilia A) or IX (Hemophilia B), has historically required lifelong factor replacement therapy. Today, groundbreaking advances in gene therapy, long-acting clotting factors, and non-factor therapies are transforming outcomes for patients around the world.

1. Traditional Treatment: Clotting Factor Replacement

The backbone of hemophilia management has been intravenous infusion of missing clotting factors:

• Hemophilia A: Factor VIII concentrates